Letters to the Editor
- PIII-13. Cromer, J.; Schofield, R. S.; Wessel, T. R.; Arant, C. B.; Zineh, I. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP61
Background: Leptin is an adipocytokine associated with vascular inflammation. The effect of high dose atorvastatin (HDA) on circulating leptin concentrations has not been studied. We investigated whether HDA modulates leptin levels in non-diabetic, normocholesterolemic individuals.Methods:...
- Thyroid hormone analogue for dyslipidemia. Kuritzky, Louis // Clinical Oncology Alert;May2010 Supplement, p10
The article discusses a research study on the use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia, published in a 2010 issue of the "New England Journal of Medicine."
- Clinical briefs. // New Zealand Doctor;2/9/2011, p21
This section offers news briefs on clinical medicine as of February 2011, including the lack of adequate evidence on the role of statins in the primary prevention of heart disease in low-risk patients, the lack of enough evidence of the effectiveness of hydrochlorothiazide at commonly used...
- Hormones Safe with Statin Therapy. Zipes, Douglas // Medical Update;2003, Vol. 28 Issue 7, p5
Focuses on a study sponsored by the National, Heart, Lung, and Blood Institute which investigated the effect of statins on the reproductive hormone levels in women. Findings of the study; Recommendations.
- Use of atorvastatin increases following PROVE-IT, REVERSAL. // PharmacoEconomics & Outcomes News;4/7/2007, Issue 525, p7
The article discusses research being done on the changes in hospital discharge prescriptions of atorvastatin in Ireland. It references a study by T. I. Barron and colleagues, published in the January 2007 issue of the "European Journal of Clinical Pharmacology." The study analyzed changes in...
- Review: Statins do not increase minor or serious symptomatic adverse events in placebo-controlled trials. Jain, Meera; Wernick, Richard // ACP Journal Club;7/1/2014, Vol. 161 Issue 2, p1
The article focuses on a systematic review that explored the proportion of side-effects of statins on patients, that are actually caused by the drug, in placebo-controlled double-blind, randomized, controlled trials. As mentioned, the review concluded that statins might increase diabetes in...
- Evidence mounts for intensive statins. // Pulse;7/26/2004, Vol. 64 Issue 30, p7
Reports on the action taken by the U.S. cardiovascular experts to set an improved target for statin treatment that goes beyond the forthcoming Joint British Societies guidelines.
- Use of Statins and Risk of Fractures. Van Staa, Tjeerd-Pieter; Wegman, Sebastiaan; De Vries, Frank; Leufkens, Bert; Cooper, Cyrus // JAMA: Journal of the American Medical Association;4/11/2001, Vol. 285 Issue 14, p1850
Presents a study investigating the risk of fracture among statin users. Design; Setting; Patients; Main outcome measures; Results; Conclusion that use of statins at dosages prescribed in clinical practice was not associated with a reduction in risk of fracture.
- The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed. Manuel, Douglas G.; Tanuseputro, Peter; Mustard, Cameron A.; Schultz, Susan E.; Anderson, Geoffrey M.; Ardal, Sten; Alter, David A.; Laupacis, Andreas // CMAJ: Canadian Medical Association Journal;4/12/2005, Vol. 172 Issue 8, p1027
Discusses a controversy surrounding the recommendations of the 2003 Canadian guidelines for the management and treatment of dyslipidemia. Comparison of the recommendations of the 2000 and 2003 Canadian guidelines for the management and treatment of dyslipidemia; Statin therapy that will be...